Behind The Data: Comprehensive Off-Target Assessment Strategies For CRISPR-Based Genome Editing Therapeutics

Assessing off-target editing is essential to building a reliable safety profile for CRISPR-based therapeutics, but different editing modalities require tailored evaluation strategies. ElevateBio combines biochemical nomination, homology-based prediction, knowledge-based annotation, and whole-exome sequencing to identify genomic sites with potential off-target activity. Deep sequencing then measures editing rates at nominated sites, while dose-response studies and testing in primary cells provide greater insight into physiological relevance. These workflows have been customized for nucleases, nickases, base editors, and reverse transcriptase editors, supporting evaluations across a wide range of editing outcomes. Positive findings can also inform protein engineering efforts designed to reduce unwanted edits.

See how this end-to-end framework connects site nomination, experimental confirmation, and biological interpretation to support stronger safety decisions as therapeutic candidates move toward the clinic.